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Objective: This study reports on a novel brain pathology in young patients with frontal lobe epilepsy (FLE) that is dis-
tinct from focal cortical dysplasia (FCD).
Methods: Surgical specimens from 20 young adults with FLE (mean age, 30 years) were investigated with histologi-
cal/immunohistochemical markers for cortical laminar architecture, mammalian target of (mTOR) pathway activation
and inhibition, cellular autophagy, and synaptic vesicle-mediated trafficking as well as proteomics analysis. Findings
were correlated with pre-/postoperative clinical, imaging, and electrophysiological data.
Results: Excessive lipofuscin accumulation was observed in abnormal dysmorphic neurones in 6 cases, but not in sev-
en FCD type IIB and 7 pathology-negative cases, despite similar age and seizure histories. Abnormal dysmorphic
neurones on proteomics analysis were comparable to aged human brains. The mTOR pathway was activated, as in
cases with dysplasia, but the immunoreactivities of nucleoporin p62, DEP-domain containing protein 5, clathrin, and
dynamin-1 were different between groups, suggesting that enhanced autophagy flux and abnormal synaptic vesicle
trafficking contribute to early lipofuscin aggregation in these cases, compared to suppression of autophagy in cases
with typical dysplasia. Cases with abnormal neuronal lipofuscin showed subtle magnetic resonance imaging cortical
abnormalities that localized with seizure onset zone and were more likely to have a family history.
Interpretation: We propose that excess neuronal lipofuscin accumulation in young patients with FLE represents a novel
pathology underlying this epilepsy; the early accumulation of lipofuscin may be disease driven, secondary to as-yet
unidentified drivers accelerating autophagic pathways, which may underpin the neuronal dysfunction in this condition.
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The cause of focal epilepsy syndromes, including fron-tal lobe epilepsies (FLEs), is being regularly advanced
through clinical, genetic, and pathological studies.1 Novel
gene mutations have been recently identified; for exam-
ple, DEPDC5 mutations are associated with familial FLE
syndromes (familial focal epilepsy with variable foci1,2 as
well as cases of sporadic FLE and with pathologically
proven focal cortical dysplasia (FCD).3–5 Historically,
studies of histologically defined malformations of cortical
development in symptomatic epilepsies have significantly
advanced identification of specific genetic defects and
causative cellular pathways.6,7 FCD is a cortical
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malformation first recognized in an epilepsy surgical
pathology series in 19718 and is now the commonest his-
tologically confirmed malformation, with a predilection
for the frontal lobe.9 Although FCD mainly occurs spo-
radically, somatic or germline mutations in mammalian
target of rapamycin (mTOR) pathway genes have now
been reported by several groups.10–12
There are currently nine subtypes of FCD, defined
by their pathological characteristics of cytoarchitectural
and associated abnormalities.13 FCD type II (FCDII) is
the best-defined subtype, characterized by dysmorphic
neurones (FCDII type A; FCDIIA) and balloon cells
(FCDII type B; FCDIIB). FCDIIB is generally associated
with favorable outcome following surgical resection,9 par-
ticularly when lesions are well defined on magnetic reso-
nance (MR) imaging (MRI) and fully resected, with
seizure-free outcomes as high as 75%14 to 87.5%.15 Mul-
timodal investigation integrating neuroimaging, electro-
physiological, and functional studies is advocated in the
surgical planning of patients with focal epilepsies, includ-
ing suspected FCD.9 However, classical imaging features
are not always present in FLE resections.
In this study of patients with FLE, we present evi-
dence for a novel and distinct neuronal pathology, char-
acterized by excessive lipofuscin accumulation in
dysmorphic neurones. We hypothesized a primary abnor-
mality in autophagy and compared multimodal investiga-
tions, including neuroimaging, electrophysiology,
proteome, mTOR, and autophagic pathway analysis, to
highlight the distinct characteristics of this pathology and
determine the possible pathomechanism underlying this
pathology.
Patients and Methods
Case Selection and Clinical Investigations
Twenty patients operated on over a 5-year period (2009–2013)
who had undergone surgical resections as a treatment of focal
drug-resistant FLE were identified from the records of the UCL
Epilepsy Society Brain and Tissue Bank (Supplementary Table
1). Surgical tissue was consented for use in research, and the
study has ethical approval (National Research Ethics Service 12/
SC/0669). Cases with vascular malformations and tumors were
excluded. Clinical records of patients, including their epilepsy
history, family history, and psychometry, were reviewed. Preop-
erative brain MRI and positron emission tomography, electro-
encephalography (EEG), videotelemetry, psychometry,
functional imaging, and intracranial EEG (IC-EEG) studies
had been carried out according to the epilepsy surgical proto-
cols at the National Hospital of Neurology and Neurosurgery
and were reviewed in each case.
All patients were studied on the 3 Tesla (T) MRI scanner
at the Epilepsy Society, Chalfont, UK. The MR protocol
included T1-weighted, T2-weighted, and fluid-attenuated
immersion recovery images using the standard epilepsy protocol
for presurgical evaluation.16 In all cases, strategies for implanta-
tion of subdural grids and/or depth electrodes were agreed at a
multidisciplinary meeting and were carried out using methodol-
ogies, as previously reported.17 In all patients studied, a putative
epileptogenic zone was identified, and patients proceeded to
resection of frontal lobe cortex and white matter, tailored
according to integrated EEG, imaging, and functional imaging
findings (Supplementary Table 1).
Neuropathology
Between two and five surgical samples were received from each
case according to regions of differing ictal activity on IC-EEG
and lesional abnormality if defined on MRI (Supplementary
Table 1). Fresh specimens were orientated for photography,
sliced, and, where available, samples of normal and macroscopi-
cally abnormal fresh tissues were snap frozen using liquid nitro-
gen. The remaining specimens were fixed in formalin for 24
hours and then further cut into 5-mm-thick tissue blocks. His-
tological and immunohistochemical investigations were then
performed on all tissue blocks using methods as published in
previous studies18 (Supplementary Table 2). Immunolabelling
was assessed qualitatively using a bright-field microscope
(Nikon Eclipse 80i; Nikon Instruments, Tokyo, Japan). For the
detection of autofluorescence, one 5-mm-thin section from each
case was washed in phosphate-buffer solution for 5 minutes
after xylene and alcohol immersions. Sections were then cover-
slipped using 4’,6-diamidino-2-phenylindole containing mount-
ing medium (Vector Laboratories Inc., Peterborough, UK).
Autofluorescence was visualized using a fluorescent microscope
with excitation wavelength at 470nm and detection at 520nm
(Carl Zeiss Microscopy, LLC, Thornwood, NY).
Electron Microscopy
Electron microscopy (EM) was performed on 2 cases with
abnormal neurones on periodic acid–Schiff (PAS) stain. Because
abnormal cells were often only focally present in the tissue sec-
tion, these abnormal regions were dissected from regions identi-
fied from the formalin-fixed, paraffin-embedded tissue blocks,
processed for EM, and examined with a Philips CM10 electron
microscope (Philips Electron Optics, Eindhoven, The Nether-
lands) and images acquired using a Megaview III digital camera
and analySIS iTEM software (Olympus Soft-Imaging Solutions
Corp., Lakewood, CO).
Proteomics
Frozen cortical samples from 5 selected cases (cases E1, E2, E8,
E13, and E19) were processed for proteomic analysis. For each
case, 10 sections of 14-mm thickness were cut on the cryostat
and collected onto polyethylene terephthalate metal frame slides
for laser capture microdissection (Leica, Milton Keynes, UK).
One additional section was collected onto a microscopic slide
(VWR International, Leicestershire, UK) and stained briefly in
0.1% toluidine blue (pH4.5) solution for 5 seconds to identify
the region of interest (ROI). Laser capture microdissection
(LCM 700; Leica) was then carried out on the ROI of multiple
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sections per case to include abnormal, dysmorphic neurones in
cases with excess focal neuronal lipofuscin (FNL) and those
with FCDIIB, and neurones in pathology-negative cases until a
total tissue area of 8 to 8.6mm2 had been dissected and collect-
ed in a 0.5-ml Eppendorf tube (VWR International).
Dissected samples were denatured using in-solution tryp-
sin digestion and prepared for MSe label-free quantitative pro-
teomics, as described previously.19 Peptide identification was
accepted if they could be established at 95% or greater proba-
bility. Quantity of proteins extracted was normalized against the
total protein of each sample (fmol/ng) and then these values
were compared between cases with FNL, pathology-negative,
and FCBIIB cases using bioinformatics resources, DAVID (ver-
sion 6.7), Ingenuity Pathway Analysis (Qiagen, Manchester,
UK), and ConsensusPathDB (version 31). p values and adjusted
p values (corrected according to Bonferroni’s method and false
discovery rate) were calculated by bioinformatics resources. For
gene ontology annotation and enriched pathway analyses, the p
value cutoff was set at 0.01, and only pathways with four or
more proteins of interest were highlighted.
Results
Of the 20 cases with FLE included this study (Supple-
mentary Table 1), 6 (E1–E6) showed the specific pathol-
ogy we term focal neuronal lipofuscinosis (FNL). These
cases were characterized by the presence of hypertrophic,
pyramidal, or globoid cortical neurones resembling dys-
morphic neurones (Fig 1A–P). The cytoplasm of these
neurones was markedly distended and ballooned with
granular material on hematoxylin-eosin (H&E; Fig 1B)
that was both PAS and Sudan Black positive, and auto-
fluoresced at an excitation wavelength of 470nm (Fig
1C–E,P) consistent with neuronal lipofuscin.20,21 This
abnormal storage material extended to the axon hillock
in some dysmorphic neurons (Fig 1C,E, arrows). We
termed these cells dysmorphic neurones with excess lipo-
fuscin (DN/L). The enlarged perikarya and abnormal
dendritic polarity of DN/L were highlighted by nonphos-
phorylated neurofilament stains (SMI32), which showed
intense labeling of cytoplasmic filaments marginalized to
the periphery of the neurone, producing “ring-like”
structures (Fig 1F,L,N). Combined PAS/SMI32 staining
showed the location of the central granular, cytoplasmic
PAS staining within peripherally arranged neurofilaments
(Fig 1G). All PAS-distended neurones had strong label-
ing with antineurofilament antibodies. There were also
interspersed normal-sized neurones with weak PAS cyto-
plasmic granular positivity, but without abnormal neuro-
filament distribution. Phosphorylated neurofilament
(SMI31) was expressed in fewer DN/L than labeled with
the SMI32 antibody, but a similar ring-like cellular pat-
tern was still observed (Fig 1L, right). DN/L were dis-
tributed across all cortical layers (E1, E3) or
predominated in the deeper cortical layers (E2, E4–E6),
but DN/L were not present in the white matter. In cases
E1 and E3, a six-layered cortical architecture was indis-
tinct (Figs 1A and 5L), whereas in other cases, as well as
at the margins, DN/L appeared scattered in cortex with
relatively preserved lamination. In case E3, DN/L were
localized to the depth of one sulcus (Fig 5J–L). Regions
populated by DN/L were more extensive and readily evi-
dent on H&E-stained sections in cases E1 to E3 com-
pared to cases E4 to E6, where changes were more subtle
with scattered, less-frequent DN/L (Supplementary Table
1).
CD34, calbindin, and nestin markers did not label
DN/L. In all 6 cases, glial fibrillary acidic protein label-
ing revealed a reactive superficial, or Chaslin’s type, glio-
sis. No balloon cells were present. White matter and
cortical myelination patterns were normal, as shown on
myelin basic protein (SMI94) immunolabeling. Iba1 and
CD68 immunolabeling revealed a mild upregulation of
microglia in the regions with DN/L and inflammatory
foci in relation to electrode track sites only. We did not
observe any relationship between the electrode track inju-
ry sites and the cortex populated by DN/L (Supplemen-
tary Table 1). Focal, granular ubiquitin immunoreactivity
was observed in a minority of cells in 4 cases with DN/L
(E1–E3 and E5; Fig 1H,O). Granular p62 cytoplasmic
immunolabeling was only observed in cases E1 and E5
(Fig 1I), with some skein-like filamentous material noted
in case E1 (Fig 1I, inset). There was no AT8 labeling in
any case. Immunohistochemistry using two anti-pS6 anti-
bodies revealed intense cytoplasmic labeling in the major-
ity of DN/L, especially when compared to adjacent or
intervening normally sized, normally labeled neurones
(Fig 1J,K). DEPDC5 immunohistochemistry did not
show evidence for strong labeling of DN/L compared to
adjacent or intervening normal cortical neurones or glia
(Fig 1K, inset). EM was carried out on cases E1 and E2.
In these sections, electron-dense deposits were observed
filling the cytoplasm, associated with lipid and compati-
ble with lipofuscin (Fig 1M).
In comparison to cases with FNL, no specific neu-
ropathology was identified in the frontal lobe samples of
7 cases (E7–E13; pathology negative). Small amounts of
PAS-positive cytoplasmic granules were observed in occa-
sional neurons of these 7 cases, but no abnormal storage
material was observed in DN or balloon cells using any
of the stains, and cortical lamination was normal on neu-
ronal nuclei (NeuN)-immunopositive sections. Inflamma-
tory foci near sites of electrode track placements were
noted. In 1 patient (E17), there was a small region of
gliosis, possibly compatible with a previous traumatic
lesion, but no definite contusion. Ubiquitin and p62
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FIGURE 1: Frontal lobe epilepsy with focal neuronal lipofuscinosis (FNL). Case E1 (A–K), case E2 (L,M), and case E3 (N–P) (A)
Enlarged, dysmorphic neurones were found throughout the cortical layers of case E1, highlighted with Neuronal Nuclei (NeuN)
staining. They were intermingled with cortical neurones of more normal size; at higher magnification (shown in inset) cytoplas-
mic material was visible, distending the cytoplasm (arrowed). (B) On hematoxylin-eosin (H&E) stains, distended neuronal cells
with accumulation of pale, cytoplasmic granular material, which was (C) periodic acid–Schiff (PAS) and (D) Sudan Black positive,
and extended into the distended axon hillock (arrowed), was evident. (E) Distinct autofluorescence of the cytoplasm was also
noted in this cell with material that extended into the axon hillock (arrow). (F) Neurofilament stain showed a distinct “ring-like”
pattern of marginalised cytoplasmic neurofilaments. (G) Colocalization of the PAS-positive storage material in these abnormal
ring-like dysmorphic neurones was confirmed through combined PAS and neurofilament (SMI32) staining. (H) Occasional neuro-
nes were positive for ubiquitin and (I) p62, but this was a less-consistent finding. (J,K) Immunolabeling, using pS6 as a marker
of mammalian target of rapamycin pathway activation, consistently demonstrated pS6-immunopositive expression in dysmor-
phic neurones in this pathology, whereas DEPDC5 immunolabeling did not show evidence for obvious increased expression in
dysmorphic neurones with excess lipofuscin (DN/L) compared to adjacent cortex and neurones or in comparison to other
pathologies (arrow indicates a DN/L in the same case). (L) In case E2, DN/L were highlighted with both phosphorylated (SMI32)
and nonphosphorylated neurofilament (SMI31) antibodies, both showing a ring-like peripheral labeling pattern surrounding the
storage material. (M) Electron microscopy confirmed electron-dense, non-membrane-bound, cytoplasmic aggregates with the
characteristic appearances of lipofuscin. (N) DN/L highlighted by neurofilament stains in case E3 with focal, weak ubiquitin
labeling (O) and cytoplasmic PAS positivity (P). Scale bar equivalent to approximately 150 microns in (A), 50 microns in (B–D),
(J,K), and 30 microns in (F–I), (L), (N–P), and 5 microns in (M).
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labeling revealed no specific labeling, except in case
E11, where skein-like filamentous neuronal inclusions
were observed. pS6-immunolabeled pyramidal and glial
cells were occasionally scattered throughout the cortex
of all cases, as previously described.18 DEPDC5 did
not show any distinct immunolabeling of neurones or
glia, with only focal weak labeling of scattered pyrami-
dal cells.
The remaining 7 cases in the series (E14–E20)
showed typical pathology of FCDIIB, with DN in the
cortex (Fig 2A) and hypomyelination of the underlying
white matter with balloon cells. Neurofilament (SMI32)
labeling did not reveal DN with ring-like expression of
neurofilaments (Fig 2B) as observed in DN/L of cases
with FNL. DN in FCDIIB cases did not have excess
neuronal storage material, or excess PAS- or Sudan
FIGURE 2: Immunoprofile of dysmorphic cells in frontal cortial dysplasia type IIB (FCDIIB). (A) FCBIIB (case E19) involving the
depth of a sulcus with dysmorphic neurones (DN) populating the cortex and spilling into the underlying white matter (neurofi-
lament stain, SMI32). (B) Unlike dysmorphic neurones with lipofuscin (DN/L) in frontal lobe epilepsy (FLE) with neuronal lipofus-
cin (FNL), DN in FCDIIB do not display marginalized neurofilaments or “ring cells” and there is no excess periodic acid–Schiff
(PAS)-positive storage material in neurones. (C) A proportion of balloon cells showed scattered PAS-positive granules, more
prominent in the periphery of some cells (inset, arrowed). (D) DN showed little autofluorescent cytoplasmic material. (E) Bal-
loon cells in FCDIIB cases showed nuclear p62 immunopositivity and, in some cells, distinct intranuclear inclusions were noted
(inset, arrowed) or (F) intense cytoplasmic labeling of balloon cells was observed. (G) pS6 immunohistochemistry showed
strong cytoplasmic labeling of DN with generally weaker labeling of balloon cells (arrow). (H) Immunohistochemistry for
DEPDC5 showed an intense paranuclear staining pattern in DN of FCDIIB, which was not noted in FNL or normal-appearing
neurones in (FLE) cases; in addition, weaker cytoplasmic labeling of balloon cells was noted (insert). (I) FCDIIA involving the
occipital lobe with SMI32 highlighting DN with intense labeling of neurofilament in the cytoplasm, but no ring-like cells are
observed as consistently noted in FNL. This sample was processed in entirety, and no balloon cells were identified. (J) Another
FCDIIA case involving the occipital lobe observed similar findings with intense SMI32-immunopositive labeling in the cell body
and dendritic processes of DN. (K) PAS staining in FCDIIA cases showed, at the most, small accumulations of PAS-positive
granules in the cytoplasm of a proportion of DN. (L) A cortical biopsy from a patient with a neurodegenerative condition and
epilepsy with genetically confirmed Niemann-Pick type C. In the inset, cortical neurons showed cell bodies distended with
weakly PAS-positive granular storage material, and prominent ring-like neurons were observed with neurofilament stains
(SMI32), reminiscent of the pattern noted in FNL cases. Scale bar in (D) is equivalent to approximately 120 microns in (A), 50
microns in (B), (E,F), (G,H), and (I–L), and 30 microns in (C).
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Black–positive material, and showed minimal autofluor-
escence (Fig 2B–D). A few balloon cells in FCDIIB cases
showed some fine granular PAS-positive staining in the
cytoplasm (Fig 2C) or sometimes at the margins of the
cell (Fig 2C, inset), reminiscent of the patterns reported
in the cell culture of balloon cells, with accumulation of
dense core lysosomes.22 Balloon cells in FCDIIB cases
also showed p62 immunopositivity, displaying both
FIGURE 3: Proteomic analysis of dysmorphic neurones with lipofuscin (DN/L) (A) Neurones selected for laser capture microdis-
section were initially outlined (green). Images showing normal-appearing neurones of a pathology-negative case (B) and DN/L
(C) of a frontal lobe epilepsy case with excess neuronal lipofuscin (asterisk; FNL) that were captured during laser microdissec-
tion. (D) Sixteen of the upregulated proteins in FNL cases (green) are involved in pathways associated with synaptic vesicles
(p<0.001; adjusted p50.004). Four of these proteins (clathrin, dynamin, syntaxin binding protein, and vesicle-associated mem-
brane protein 2) had been described in a previous study investigating the proteome of lipofuscin in aged and Alzheimer’s-
diseased human brains (Ottis et al, 2012). At the presynaptic terminal of neurones, synaptic vesicles are actively loaded with
neurotransmitters (NT) and then they are docked and “primed” at the “active zone” of the plasma membrane. When action
potential arrives and depolarisation occurs, NT are released by exocytosis (fusion). Vesicles are retrieved through endocytosis.
Diagram is adapted from WikiPathways.org (Pathway: WP2267) and Kyoto Encyclopaedia of Genes and Genomes (KEGG).
Genes and proteins in (D) are as follow: AP2M15AP2 complex subunit mu; ATP6V1B25ATPase, H1 transporting lysosomal
56/58kDa, V1 subunit B2; ATP6V1A5ATPase, H1 transporting, lysosomal 70-kDa V1 subunit A; CLTC5 clathrin heavy chain 1;
DNM15dynamin 1.39; RAB3A5Ras-related protein Rab 3A; PARK75protein DJ 1 (Parkinson protein 7); RIMS15 regulating
synaptic membrane exocytosis 1; SLC1A35excitatory amino acid transporter 1; SLC25A45 adenosine diphosphate (ADP)
adenosine triphosphate (ATP) translocase 1; SNAP5 synaptosomal-associated protein; STX5 syntaxin; STXBP15 synatxin bind-
ing protein 1; SYN5 synapsin; SYP5 synaptophysin; SYT15 synaptotagmin 1. Numbers in brackets refer to fold increase of
proteins in DN/L of FNL compared to pathology-negative cases. Scale bar in (B) and (C)510mm. NSF5N-ethylmaleimide-
sensitive factor.
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nuclear (Fig 2E) and intense cytoplasmic labeling
patterns (Fig 2F) with dot-like intranuclear p62
inclusions noted (Fig 2E, inset). In case E14, p62-
positive DN were also observed. Ubiquitin immuno-
reactivity was not observed in balloon cells or DN.
No tangles or AT8 immunolabeling were observed
in any of the cases. pS6 immunohistochemistry
showed intensely labeled DN compared to balloon
cells (Fig 2G), as previously noted.18 Prominent par-
anuclear aggregates with DEPDC5 were noted in
the DN (Fig 2H), with some cytoplasmic labeling
as well as variable cytoplasmic granular staining of
balloon cells (Fig 2H, inset) with occasional intranu-
clear dot-like inclusions.
None of the cases in this series showed typical
FCDIIA pathology.13 Three archival FCDIIA cases from
different cortical regions (Fig 2I–K) were reviewed for
comparison to FNL. No DN/L were observed in any of
the cases, although intense SMI32-immunopositive
enlarged neurones were present.
FIGURE 4: Clathrin and dynamin-1 immunohistochemistry in frontal lobe epilepsy (FLE) pathologies. (A) Cytoplasmic storage
material in the dysmorphic neurones of FLE cases with excess neuronal lipofuscin (FNL) was strongly immunopositive for cla-
thrin. (B,C) Most dysmorphic neurones with excess lipofuscin (DN/L) in FNL also expressed dynamin-1 in the cytoplasm, to a
variable extent and intensity (arrowhead), but a proportion of neurones were distinctively dynamin-1 negative, as shown
(arrows) in cases E1 (B) and E3 (C). (D) In pathology-negative FLE resections, small amounts of weakly clathrin-positive cytoplas-
mic granular material was noted in neurones, but intense labeling for dynamin-1, as illustrated in (E), in normal white matter
interstitial neurones. (F) Sparse labeling of clathrin was observed in the dysmorphic neurones (DN) of FCDIIB although (G)
more-consistent labeling of balloon cells with a peripheral granular pattern was noted. (H) Dynamin-1 immunohistochemistry
typically showed intense cytoplasmic labeling of DN in FCDIIB, but (I) a striking lack of labeling of balloon cells was apparent.
Scale bar in (A–F) and (H) is equivalent to 50 microns and (G) and (I) to approximately 30 microns.
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FIGURE 5: Clinical investigations in cases with frontal lobe epilepsy case with excess neuronal lipofuscin (FNL). Case E1 (A–C).
Magnetic resonance (MR) imaging (MRI): A subtle area of blurring in the right frontal gray matter was noted on T1-weighted
images preoperatively (A); the corresponding postoperative resection cavity is noted in (B). (C) Position of intracranial grids
overlying the frontal cortex is marked with a dashed line showing the approximate area of the right frontal lobe for planned
surgical resection, sparing the primary motor cortex. Oval areas demarcate the following functional fields: purple oval (primary
motor); blue oval (front eye field); and green oval (face motor). Red circles indicate ictal onset, pink circles early spread within
1 second, and orange circles late spread within 1.5 to 2 seconds. Case E2 (D–F); (D) MRI T1-weighted coronal image showed
no abnormality. (E) Electroencephalography (EEG) studies with grid in place; contact points involved in seizure activity are indi-
cated as dark pink circles and late evolving regions after 50 seconds as pale pink circles; regions with interictal spikes (orange
circles, higher amplitude; yellow circles, lower amplitude) are also shown. (F) Resected frontal lobe specimen was macroscopi-
cally normal following fixation and slicing at 5-mm intervals. (G) Case E3 (G–L): MRI T2-weighted image showing subtle blurring
of gray/white matter interface in the left superior frontal gyrus. (H) Intracranial ictal EEG showed fast activity (80Hz [yellow])
and repetitive spiking (red oval outline) over the superior frontal gyrus. (I) Resected specimen from the seizure onset zone was
unremarkable apart from meningeal congestion and is shown in postfixation 5-mm slices in (J) through the main sulcus. (K) A
9.4 Tesla (T) MRI was performed on the fixed tissue slice shown in (J) overnight using 9.4T MR scanner (Agilent Technologies,
Santa Clara, CA) with sequences including T2 (as shown in K) that showed ill-defined mild blurring of the cortex and white mat-
ter in the depths of the sulcus at the deep resection margin (K, arrow), which corresponded to the region with localized dys-
morphic neurones with excess lipofuscin and dyslamination on histology, as shown in (L), from the same region with neuronal
nuclei (NeuN) and SMI32 immunolabeling. This case has been reported in a previous study of quantitative MRI analysis in epi-
lepsy resections (Reeves et al, Brain Pathology, 2015). Bar in (I) is equivalent to 1cm.
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Proteomics Analysis
This was carried out on 2 cases with FNL (E1, E2), 2
pathology-negative cases (E8, E13), and 1 FCDIIB case
(E19). One hundred fifty-nine proteins were identified
in the proteomes of neurones in cases with FNL and
pathology-negative cases. Expression of 76 proteins was
found to be higher in DN/L in cases with FNL com-
pared to neurones in pathology-negative cases (fold
change, > 1; Fig 3A–D). Most of the upregulated pro-
teins in FNL cases were intracellular proteins, found in
membrane-bounded organelles and vesicles. Twenty-four
of the upregulated proteins in cases with FNL were
lipofuscin-related proteins, which had been reported in a
previous proteomic study that had extracted 49 major
lipofuscin proteins from brain samples of a 64-year-old
patient with Alzheimer’s disease (AD) with Braak stage
IV and Consortium to Establish a Registry for Alz-
heimer’s Disease (CERAD) grade C and 2 normal aging
donors of 85 (Braak I, CERAD grade 0) and 83 years
(Braak II, CERAD grade 0).23 This supported the
impression of an excess of lipofuscin-related proteins in
FNL. Upregulated proteins in FNL cases were noted to
involve various pathways identified from pathway data-
bases (p< 0.01). In particular, clathrin, dynamin-1, adap-
tor protein-2 (AP2), synapsin, syntaxin, synaptotagmin,
and vesicle-associated membrane proteins are involved in
synaptic clathrin-mediated vesicle pathways (p5 0.004;
Fig 3D), which have roles in autophagy, phagosome, and
lysosomal pathways.24,25 In contrast, these vesicle-
associated proteins showed either no changes or fold
decrease in FCDIIB compared to pathology-negative
cases.
Further immunohistochemistry was carried out for
clathrin and dynamin-1 in all cases with FNL, and
pathology-negative (E7–E9) and FCDIIB cases (E13 and
E17–E18; Fig 4A–I). Using anti-clathrin antibodies spe-
cific for the c-terminus of the heavy chain (Fig 4), strong
granular immunopositivity was observed in the cytoplasm
and axon hillocks of the majority of DN/L in cases with
FNL, with a similar distribution to PAS (Fig 4A). There
were minor degrees of cytoplasmic positivity for clathrin
in neurones in pathology-negative cases (Fig 4D). In
FCDIIB cases, very sparse clathrin-labeled DN were
observed (Fig 4F), and focal granular clathrin labeling of
balloon cells, often distributed at the margins of the
cytoplasm, was also noted (Fig 4G). Anti-dynamin-1,
specific for the c-terminus of dynamin-1, showed variable
labeling in cases with FNL, with some unlabeled DN/L,
whereas the majority showed cytoplasmic positivity (Fig
4B–C). Normal-appearing cortical neurones, including
interstitial white matter neurones of normal morphology,
were diffusely positive for dynamin-1 in pathology-
negative cases (Fig 4E). The DN in FCDIIB cases
showed mainly intense cytoplasmic labeling (Fig 4H),
but balloon cells were strikingly negative, for dynamin-1
(Fig 4I).
Clinical Investigations and Outcome
A review of clinical data (Supplementary Table 1)
revealed no significant difference in mean age of onset of
epilepsy in cases with FNL (11.8 years) compared to
pathology-negative (8 years) and FCDIIB cases (9.2
years; p5 0.29). Mean age at surgery was between 30
and 31 years in all three pathology groups. A family his-
tory of epilepsy in a first-degree relative was noted in 3
of 6 cases with FNL, but in none of the pathology-
negative or FCDIIB cases. The preoperative MRI was
abnormal in 5 of 6 cases with FNL, with subtle abnor-
malities in the cortical/white matter interface and blur-
ring of the boundaries and cortical signal change
(Supplementary Table 1; Fig 5). In contrast, only 2 of 7
pathology-negative cases showed any cortical MRI abnor-
mality, whereas 5 of 7 FCDIIB cases were abnormal,
showing MRI features typical of FCDIIB, including the
hallmark “transmantle” sign, in 2 cases (E18 and E19).
IC-EEG recordings, using depth electrodes and/or sub-
dural strips or grids, had been carried out preoperatively
in all 20 cases, and in the majority of cases, separate
samples were resected from regions of different activity
including: (1) seizure focus/onset zone and (2) regions of
secondary involvement (early and late spreading zones;
Supplementary Table 1). DN/L were noted in samples
from the seizure onset site in 5 of 6 cases with FNL and
also in regions with secondary EEG involvement in 2
cases. There was no significant difference in postoperative
outcomes between the three groups, with 2 of 6 patients
seizure free in the FNL group, compared to 6 of 7 in
FCDIIB and 2 of 7 in the pathology-negative group
(p5 0.073), but this is a small series. It was not possible
to comment on the completeness of resection in the
majority of cases with FNL; in only 1 case with FNL
(E3), the lesion was localized to the bottom of a sulcus
and appeared to be completely resected during surgery,
and this patient was seizure free postoperatively. There
was no significant difference in the length of follow-up
(range, between 2 and 6 years) between the three groups.
Discussion
We describe a novel neuropathological finding in young-
adult patients with focal epilepsy localizing to the frontal
lobe, characterized by excessive lipofuscin accumulation
within dysmorphic-appearing neurones. The proteome of
DN/L in cases with FNL compared to neurones in
pathology-negative FLE cases revealed increased
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lipofuscin-related proteins, comparable to the patterns
noted in aged and AD human brains. FNL was typically
associated with more-subtle cortical MRI abnormalities
compared to FCDIIB, was present in the active seizure
onset site, and was associated with a family history of
epilepsy in half the cases. Although several histological
features initially suggested a cortical dysplasia, this
pathology appeared distinct from FLE with typical
FCDIIB. We propose that this represents a distinct neu-
ronal pathology in focal epilepsy involving the frontal
lobe and is secondary to enhanced cellular autophagy.
FNL Is Distinct From FCDIIA and IIB
FCDIIB more commonly arises in the frontal lobes based
on ascertainment from epilepsy surgical series.26 Hall-
mark features typical of FCDIIB (presence of balloon
cells and dysmorphic neurones) were also observed in
one third of our FLE patients. Although no frontal
FCDIIA cases were present in this series, a comparison
with FCDIIA from other regions was made. Several lines
of evidence in our study suggest that FNL is a distinct
pathology from FCDIIA and IIB: (1) presence of excess
neuronal lipofuscin (confirmed through histological
stains, electron and fluorescent microscopy, proteomics
where possible), which was not evident in FCDIIA and
IIB or pathology-negative cases, despite patients having
similar ages and duration of epilepsy; (2) ring-like rear-
rangement of neurofilaments in DN/L surrounded the
accumulation of lipofuscin and was never observed in
DN of FCDIIA and IIB (but we have observed this in
neuronal storage disorders (as illustrated in Fig 2L); (3)
DN/L of FNL cases were confined to the cortical layers
and did not “trail” into the underlying white matter,
unlike FCDIIA and IIB; (4) expression patterns of ubiq-
uitin, p62, clathrin, and dynamin-1 were different in
abnormal cell types in FNL compared to FCDIIB cases;
and (5) a suggestion of different clinical features in this
new pathology, with MRI features being more subtle in
cases with FNL compared to typical FCDIIB, and an
impression of better postoperative seizure control in
FCDIIB (based on this current small series as well as the
literature9), with 86% of FCDIIB cases becoming seizure
free compared to 33% of cases with FNL. Furthermore,
there were no “overlap” cases to suggest that cases with
FCDIIB will accumulate FNL over time or that cases
with FNL will develop FCDIIB.
Abnormal Autophagic and mTOR Pathways
in FNL
Lipofuscin is composed of approximately two thirds pro-
teins, one third lipid, and a small amount of carbohy-
drates and metals.27 Though the number of cases in this
analysis is small, with the possible exclusion of some pro-
teins insoluble to trypsin digestion, our proteomic studies
nevertheless revealed an upregulation of lipofuscin-related
proteins in the DN/L in cases with FNL, reinforcing
findings in our immunohistochemical and EM studies.
Previous proteomic studies of lipofuscin in the postmor-
tem aging human brain (from the ninth decade) detected
abnormalities of mitochondrial, cytoskeletal, and mem-
branous proteins.23 Consistently, these proteins were also
observed in high levels in our proteomic analysis of DN/
L in cases with FNL, and yet these patients in our series
were only in their third to fourth decades. Thus, the
advanced accumulation of lipofuscin in DN/L of young
patients with FNL appears not to be age related, but dis-
ease linked. Lipofuscin accumulation is a normal physio-
logical process of the aging cell,28 where accumulation is
attributed to incomplete digestion of proteins and lipids
over the cell life span. However, upregulation of
lipofuscin-related proteins in young patients with FNL in
this study may be attributed to impairments to the auto-
phagic pathway. Autophagy in normal cellular homeosta-
sis enables removal or recycling of damaged proteins and
organelles and is an essential mechanism for cell surviv-
al.29 Impaired autophagy is implicated in several neuro-
degenerative diseases.32 p62 is an ubiquitin-binding
protein and a substrate of autophagy, and its levels are
inversely associated with autophagy flux.30,31 In this
study, we observed infrequent labeling of DN/L with
p62 in cases with FNL, in contrast to the frequent strong
expression in abnormal cells of FCDIIB cases. These
findings are consistent with previous studies, which
reported p62 labeling in the nucleus of balloon cells, but
not DN, and absent ubiquitin expression in balloon
cells,22 and another study, which reported nuclear and
cytoplasmic p62 labeling in both balloon cells and DN
in FCDIIB, colocalizing with ubiquitin.32 These observa-
tions support impaired autophagy cellular mechanisms
operating in FCDIIB, in contrast to evidence for
enhanced autophagy flux, resulting in excess lipofuscin
accumulation, in cases with FNL (Fig 6).
mTOR is a nutrient-responsive kinase, and it is one
of the major inhibitors of autophagy.28 When the intra-
cellular concentrations of growth factors/nutrients (carbo-
hydrate, amino acid, and adenosine triphosphate [ATP])
are high, the mTOR pathway is activated and autophagy
is inhibited: mTOR complex 1 (mTORC1) will phos-
phorylate the transcription factor, TFEB, to prevent its
translocation to the nucleus. Conversely, during starva-
tion, mTORC1 is inhibited, to allow autophagy to begin;
but during prolonged starvation, mTORC1 is reactivated
and autophagic lysosome reformation (ALR) is initiat-
ed.33 mTOR pathway dysregulation is well recognized in
Liu et al: Frontal Lobe Epilepsy With Lipofuscin
December 2016 891
FCD and in tubers.34,35 Elevated expression of pS6 and
other phosphoproteins in the mTOR pathway has been
reported in DN and balloon cells of FCDIIB
patients.18,36–38 More recently, activating somatic muta-
tions in MTOR have been shown in FCDIIA and IIB
cases,10,12 and DEPDC5 mutations have been reported in
familial cases of FCDIIA.39 Activation of mTOR has
also been more widely implicated in different epilepsy
pathologies18 and epileptogenic mechanisms.40 In this
study, we again utilized pS6 as a reliable marker of the
activated mTOR pathway,36 and the strong immunoreac-
tivity for pS6 supported mTOR pathway activation in
the DN/L of cases with FNL. In general, we observed
less labeling in the abnormal cell types of cases with
FNL for DEPDC5 protein compared to labeling
observed in FCDIIB, suggesting differences in pathway
activation. In FCDIIB, the net effect of mTOR activa-
tion is suppression of autophagy,22 but this appears to be
overridden in cases with FNL by as-yet unidentified driv-
ers of autophagy (Fig 6). Future genetic studies will need
FIGURE 6: Possible pathways of abnormal autophagy in cases with frontal lobe epilepsy case with excess neuronal lipofuscin
(FNL) compared to frontal cortial dysplasia type IIB (FCDIIB). Normally, inactivation of mammalian target of rapamycin (mTOR)
activity leads to lysosomal biogenesis and autophagy, a process where autophagosomes fuse with lysosomes to degrade intra-
cellular materials. In FCDIIB, there is mTOR activation with resultant suppression of autophagy (top row). In FNL, despite
mTOR activation, there is enhanced autophagy. mTOR, in this pathology, may enhance the process of autophagy lysosome
reactivation (ALR), which is clathrin dependent, leading to excess cellular clathrin as well as prolonging inhibition of autophagy,
resulting in accumulation of nondegraded materials at various stages of autophagy or ALR processes, thus increasing formation
of lipofuscin. Clathrin-coated vesicles and trafficking (yellow); lysosomes (green); lipofuscin cellular accumulation (dark red); and
cytoplasmic neurofilaments (orange). PAS5periodic acid–Schiff.
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to be conducted to determine whether there are any spe-
cific mutations directly driving mTOR pathway activa-
tion in FNL.
Evidence for Abnormal Clathrin-Mediated
Vesicle Formation and Trafficking in FNL
Proteomic studies showed that DN/L in cases with FNL
had higher amounts of clathrin and its interacting pro-
teins compared to pathology-negative cases. Elevated cla-
thrin levels have previously been reported in the normal
aged human brain.23 We confirmed this finding with
immunohistochemistry, which showed prominent label-
ing of DN/L with anticlathrin antibodies compared to
normal neurones and DN in FCDIIB, with only focal,
marginal labeling of balloon cells noted. Clathrin and its
adaptor proteins regulate receptor-mediated endocytosis
by stabilizing the small invaginations of the plasma mem-
brane used to retrieve or absorb specific membranous
ligands and receptors. Clathrin is integral to the formation
of the preautophagosome in autophagy,41 to neurotrans-
mitter recycling at the nerve terminal42,43 as well as during
ALR, where tubules and vesicles are extruded from autoly-
sosomes in a clathrin- and phosphatidylinositol-4,5-
bisphosphate–dependent manner to reform lysosomes.25,44
Expression of clathrin on mature lysosomes has previously
been reported, and it is believed that this interaction facili-
tates the retrograde transport of materials out of the lyso-
somes to maintain homeostasis.45 The increased cellular
expression of clathrin in cases with FNL may mark the
presence of increased numbers of unprocessed clathrin-
containing preautophagosomes, or autophagosomes, or the
clustering of clathrin on lysosomes (following ALR and
lysosomal retrograde transport) as a result of prolonged
autophagy attenuation in DN/L (Fig 6). Clathrin dysregu-
lation may be pivotal to the observed cytopathology in
cases with FNL and, given that clathrin-mediated endocy-
tosis is also involved in neurotransmitter trafficking at the
presynaptic terminal, fluxes in cellular levels could poten-
tially influence neuronal activity and have a direct role in
excitability.
Dynamin-1 is a central nervous system–specific
GTPase essential for clathrin-mediated endocytosis and
vesicle trafficking. Dynamin-1 protein was also increased
in protein fractions of cases with FNL. Dynamin-1 also
has roles in autophagic pathways and activity-dependent
synaptic vesicle recycling.46 Intriguingly, cytoplasmic neg-
ativity was observed in a subpopulation of DN/L cells, as
well as striking negativity in balloon cells, which could
indicate a specific cellular dysfunction of dynamin-1 link-
ing these pathologies. Genetic mutations of DNM1,
which encodes dynamin-1, have been recently recognized
in epileptic encephalopathies47 and cause epilepsy in
experimental models48,49 and further investigation in
cases with FNL and FCDIIB is warranted.
In conclusion, we have identified a novel neuro-
pathological abnormality in FLE patients, mimicking a
cortical dysplasia, but distinct, from recognised types of
FCDIIA or IIB, as supported by histological and proteo-
mics analysis. We have demonstrated abnormalities in
autophagic pathways, which have likely resulted in the
observed neuronal dysmorphism. The findings from this
study have highlighted a family history in cases with
FNL, which could signify an underlying genetic predis-
position to FNL. Future work will be directed to identify
candidate genes/pathways. This study also identifies fur-
ther lines of investigation of genes regulating autophagy
and vesicle trafficking that may underpin this pathology,
its contribution to epileptogenesis, and lead to identifica-
tion of novel therapeutic targets.
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